Novel approaches to treating advanced systemic mastocytosis
JA Gilreath,1 L Tchertanov,2 MW Deininger31Department of Pharmacotherapy, College of Pharmacy and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; 2Centre de Mathématiques et de Leurs Applications (CMLA-CNRS), ENS Paris-Saclay, Cachan 94235, France; 3Division...
Guardado en:
Autores principales: | Gilreath JA, Tchertanov L, Deininger MW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3b950dcf31fb4f92945febf9a423a7bb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Precision Medicine in Systemic Mastocytosis
por: Maura Nicolosi, et al.
Publicado: (2021) -
Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
por: Daria A. Filonenko, et al.
Publicado: (2021) -
Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris MO, et al.
Publicado: (2017) -
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021) -
DNA methylation profile in patients with indolent systemic mastocytosis
por: Aleksandra Górska, et al.
Publicado: (2021)